prikaz prve stranice dokumenta A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies
  Preuzmi
PDF 3.43 MB
Znanstveni rad - Izvorni znanstveni rad
A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies
Pharmaceutics, 13 (2021), 6; 795. https://doi.org/10.3390/pharmaceutics13060795
Nižić Nodilo, Laura; Ugrina, Ivo; Špoljarić, Drago; Amidžić Klarić, Daniela; Jakobušić Brala, Cvijeta; Perkušić, Mirna; Pepić, Ivan; Lovrić, Jasmina; Saršon, Vesna; Safundžić Kučuk, Maša; Zadravec, Dijana; Kalogjera, Livije; Hafner, Anita

Citirajte ovaj rad

Nižić Nodilo, L., Ugrina, I., Špoljarić, D., Amidžić Klarić, D., Jakobušić Brala, C., Perkušić, M. ... Hafner, A. (2021). A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies. Pharmaceutics, 13. (6). doi: 10.3390/pharmaceutics13060795

Nižić Nodilo, Laura, et al. "A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies." Pharmaceutics, vol. 13, br. 6, 2021. https://doi.org/10.3390/pharmaceutics13060795

Nižić Nodilo, Laura, Ivo Ugrina, Drago Špoljarić, Daniela Amidžić Klarić, Cvijeta Jakobušić Brala, Mirna Perkušić, Ivan Pepić, et al. "A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies." Pharmaceutics 13, br. 6 (2021). https://doi.org/10.3390/pharmaceutics13060795

Nižić Nodilo, L., et al. (2021) 'A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies', Pharmaceutics, 13(6). doi: 10.3390/pharmaceutics13060795

Nižić Nodilo L, Ugrina I, Špoljarić D, Amidžić Klarić D, Jakobušić Brala C, Perkušić M, i sur.. A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies. Pharmaceutics [Internet]. 26.05.2021. [pristupljeno 07.11.2024.];13(6). doi: 10.3390/pharmaceutics13060795

L. Nižić Nodilo, et al., "A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies", Pharmaceutics, vol. 13, br. 6, Svibanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:605462. [Citirano: 07.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:605462
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies
AutorLaura Nižić Nodilo
AutorIvo Ugrina
AutorDrago Špoljarić
AutorDaniela Amidžić Klarić
AutorCvijeta Jakobušić Brala
AutorMirna Perkušić
AutorIvan Pepić
AutorJasmina Lovrić
AutorVesna Saršon
AutorMaša Safundžić Kučuk
AutorDijana Zadravec
AutorLivije Kalogjera
AutorAnita Hafner
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA OTORINOLARINGOLOGIJU I KIRURGIJU GLAVE I VRATA)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Otorinolaringologija
Sažetak (engleski)
Nasal route of administration offers a unique opportunity of brain targeted drug delivery via olfactory and trigeminal pathway, providing effective CNS concentrations at lower doses and lower risk for adverse reactions compared to systemic drug administration. Therefore, it has been recently proposed as a route of choice for glucocorticoids to control neuroinflammation processes in patients with severe Covid-19. However, appropriate delivery systems tailored to enhance their efficacy yet need to emerge. In this work we present the development of sprayable brain targeting powder delivery platform of dexamethasone sodium phosphate (DSP). DSP-loaded microspheres, optimised employing Quality-by-Design approach, were blended with soluble inert carriers (mannitol or lactose monohydrate). Powder blends were characterized in terms of homogeneity, flow properties, sprayability, in vitro biocompatibility, permeability and mucoadhesion. Nasal deposition studies were performed using 3D printed nasal cavity model. Mannitol provided better powder blend flow properties compared to lactose. Microspheres blended with mannitol retained or enlarged their mucoadhesive properties and enhanced DSP permeability across epithelial model barrier. DSP dose fraction deposited in the olfactory region reached 17.0% revealing the potential of developed powder platform for targeted olfactory delivery. The observed impact of nasal cavity asymmetry highlighted the importance of individual approach when aiming olfactory region.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPharmaceutics
Brojčani podacivol. 13, br. 6, 795
e-ISSN1999-4923
DOIhttps://doi.org/10.3390/pharmaceutics13060795
URN:NBNurn:nbn:hr:105:605462
Datum objave publikacije2021-05-26
ProjektŠifra: UIP-2017-05-4592
Naziv (hrvatski): Optimiranje depozicije raspršenih in situ gelirajućih i praškastih terapijskih sustava u nosnoj šupljini
Kratica: OptiNasalSpray
Voditelj: Anita Hafner
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: UIP
URL dokumentahttps://www.mdpi.com/1999-4923/13/6/795
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2021-12-16 10:08:34